Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

Clinical Cancer Research

Volumn 23, Issue 8, 2017, Pages 1929-1936

  Segal, Neil H ^a   Logan, Theodore F ^b   Hodi, F Stephen ^c   McDermott, David ^d   Melero, Ignacio ^e   Hamid, Omid ^f   Schmidt, Henrik ^g   Robert, Caroline ^h   Chiarion Sileni, Vanna ⁱ   Ascierto, Paolo A ^j   Maio, Michele ^k   Urba, Walter J ^l   Gangadhar, Tara C ^m   Suryawanshi, Satyendra ⁿ   Neely, Jaclyn ⁿ   Jure Kunkel, Maria ^n,q   Krishnan, Suba ⁿ   Kohrt, Holbrook ^o   Sznol, Mario ^p   Levy, Ronald ^o  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

^f Angeles Clinic and Research Institute   (United States)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h UNIVERSITÉ PARIS SACLAY   (France)

ⁱ VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k UNIVERSITY HOSPITAL OF SIENA   (Italy)

^l PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^m UNIVERSITY OF PENNSYLVANIA   (United States)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p YALE CANCER CENTER   (United States)

^q MEDIMMUNE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CORTICOSTEROID; CYTOKINE; INTERFERON; URELUMAB; ANTINEOPLASTIC AGENT; CD137 LIGAND; MONOCLONAL ANTIBODY; TNFSF9 PROTEIN, HUMAN;

ABDOMINAL PAIN; ACUTE HEPATITIS; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOIMMUNE HEPATITIS; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CELLULITIS; COLORECTAL CANCER; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FREQUENCY ANALYSIS; GENE INDUCTION; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; IMMUNOLOGY; KIDNEY CANCER; LEUKOPENIA; LIVER DISEASE; LIVER FAILURE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MELANOMA; MONOTHERAPY; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOLID MALIGNANT NEOPLASM; THROMBOCYTOPENIA; VOMITING; AGONISTS; CLINICAL TRIAL; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS;

4-1BB LIGAND; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASMS;

EID: 85018841234     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1272     Document Type: Article

References (26)

1. U.S. Food and Drug Administration. FDA approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/.
2. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermottDF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
3. Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 2015;33:1889-94.
4. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
5. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res 2014; 20:6258-68.
6. Shin DS, Ribas A. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next? Curr Opin Immunol 2015;33:23-35.
7. Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. CurrOpin Immunol 2013;25:230-7.
8. Vinay DS, Kwon BS. 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy. BMB Rep 2014;47:122-9.
9. Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE. Boosting cancer immunotherapy with anti-CD137 antibody therapy. Clin Cancer Res 2015;21: 3113-20.
10. Melero I, Shuford WW, Newby SA, Aruffo A, Ledbetter JA, Hellström KE, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997;3:682-5.
11. Sznol M, Hodi FS, Margolin K,McDermott D, Ernstoff M, Kirkwood J, et al. Phase I/II study of BMS-663513, a fully-human anti-CD137 agonist monoclonal antibody, in patients with advanced cancer. J Clin Oncol 2008;26:15s (suppl; abstr 3007).
12. Jure-Kunkel MN, Calarota S, Girit E, Abraham R, Balimane P, Price K, et al. Functional characterization of fully human anti-CD137 antibodies. In: Proceedings of the 97th Annual Meeting of the American Association for Cancer Research; 2006 Apr 1-5; Washington, DC. Philadelphia, PA: AACR; 2006. Abstract nr 4759.
13. Fisher TS, Kamperschroer C, Oliphant T, Love VA, Lira PD, Doyonnas R, et al. Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity. Cancer Immunol Immunother 2012;61:1721-33.
14. Chacon JA, Wu RC, Sukhumalchandra P, Molldrem JJ, Sarnaik A, Pilon-Thomas S, et al. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+)melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy. PLoS One 2013;8:e60031.
15. Melero I, Gangadhar TC, Kohrt HE, Segel NH, Logan T, Urba WJ, et al. A phase I study of the safety, tolerability, pharmacokinetics, and immunoregulatory activity of urelumab (BMS-663513) in subjects with advanced and/or metastatic solid tumors and relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). J Clin Oncol 31, 2013; (suppl; abstr TPS3107).
16. Kocak E, Lute K, Chang X, May KF Jr, Exten KR, Zhang H, et al. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res 2006;66:7276-84.
17. Niu L, Strahotin S, Hewes B, Zhang B, Zhang Y, Archer D, et al. Cytokinemediated disruption of lymphocyte trafficking, hemopoiesis, and induction of lymphopenia, anemia, and thrombocytopenia in anti-CD137-treated mice. J Immunol 2007;178:4194-213.
18. Dubrot J, Milheiro F, Alfaro C, Palazón A, Martinez-Forero I, Perez-Gracia JL, et al. Treatmentwith anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother 2010;59:1223-33.
19. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.
20. Lee SC, Ju SA, Sung BH, Heo SK, Cho HR, Lee EA, et al. Stimulation of the molecule 4-1BB enhances host defense against Listeria monocytogenes infection in mice by inducing rapid infiltration and activation of neutrophils and monocytes. Infect Immun 2009;77:2168-76.
21. Houot R, Kohrt HE, Marabelle A, Levy R. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol 2011;32:510-6.
22. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, et al. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423-32.
23. Kohrt HE, Colevas AD, Houot R, Weiskopf K, Goldstein MJ, Lund P, et al. Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest 2014; 124:2668-82.
24. Dai M, Wei H, Yip YY, Feng Q, He K, Popov V, et al. Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation. J Immunother 2013;36:248-57.
25. Wei H, Zhao L, Li W, Fan K, Qian W, Hou S, et al. Combinatorial PD-1 blockade and CD137 activation has therapeutic efficacy in murine cancer models and synergizes with cisplatin. PLoS One 2013;8: e84927.
26. Mueller AMS,Hebb J, Idit Sagiv-Barfi I, Marabelle A, Houot R, Rajapaksa A, et al. Sequential tumor and dual immune targeted immunotherapy: antilymphoma activity of rituximab with 4-1bb stimulation and PD-1 blockade. J Immunother Cancer 2014;2(Suppl 3):P106.